- Home
- BLTE vs NAMS Comparison
BLTE vs NAMS Comparison
Compare BLTE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- NAMS
- Stock Information
- Founded
- BLTE 2018
- NAMS 2019
- Country
- BLTE United States
- NAMS Netherlands
- Employees
- BLTE N/A
- NAMS N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BLTE Health Care
- NAMS Health Care
- Exchange
- BLTE Nasdaq
- NAMS Nasdaq
- Market Cap
- BLTE 2.1B
- NAMS 2.5B
- IPO Year
- BLTE 2022
- NAMS N/A
- Fundamental
- Price
- BLTE $60.48
- NAMS $17.96
- Analyst Decision
- BLTE Strong Buy
- NAMS Strong Buy
- Analyst Count
- BLTE 4
- NAMS 8
- Target Price
- BLTE $96.67
- NAMS $42.88
- AVG Volume (30 Days)
- BLTE 32.1K
- NAMS 932.6K
- Earning Date
- BLTE 08-08-2025
- NAMS 08-06-2025
- Dividend Yield
- BLTE N/A
- NAMS N/A
- EPS Growth
- BLTE N/A
- NAMS N/A
- EPS
- BLTE N/A
- NAMS N/A
- Revenue
- BLTE N/A
- NAMS $47,140,000.00
- Revenue This Year
- BLTE N/A
- NAMS N/A
- Revenue Next Year
- BLTE N/A
- NAMS N/A
- P/E Ratio
- BLTE N/A
- NAMS N/A
- Revenue Growth
- BLTE N/A
- NAMS 586.97
- 52 Week Low
- BLTE $43.70
- NAMS $14.06
- 52 Week High
- BLTE $86.53
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- BLTE 46.26
- NAMS 42.30
- Support Level
- BLTE $58.55
- NAMS $20.06
- Resistance Level
- BLTE $62.49
- NAMS $21.91
- Average True Range (ATR)
- BLTE 1.81
- NAMS 1.41
- MACD
- BLTE -0.40
- NAMS -0.20
- Stochastic Oscillator
- BLTE 26.19
- NAMS 4.45
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.